Results for tag: "Roactemra"

The Roactemra market is a subset of the larger Immune Disorders Drugs market. It is focused on the development and commercialization of drugs that target the immune system to treat a variety of conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease. Roactemra is a biologic drug that works by blocking the action of a protein called tumor necrosis factor (TNF). This protein is involved in the inflammation process, and blocking it can reduce inflammation and improve symptoms. The Roactemra market is highly competitive, with many companies vying for market share. Some of the major players in the market include Roche, Novartis, AbbVie, and Pfizer. Other companies, such as Amgen, Merck, and Johnson & Johnson, are also active in the market. Show Less Read more